These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31378578)

  • 1. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes.
    Di Nunno V; Mollica V; Santoni M; Gatto L; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2019 Oct; 17(5):e871-e877. PubMed ID: 31378578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
    ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis.
    Rizzo A; Merler S; Sorgentoni G; Oderda M; Mollica V; Gadaleta-Caldarola G; Santoni M; Massari F
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1237-1243. PubMed ID: 34407702
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
    Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
    Liu Z; Zhang T; Ma Z; Zheng S; Chen J; Wu Z; Zheng X; Li X; Liu Z
    Am J Clin Oncol; 2020 Apr; 43(4):288-297. PubMed ID: 31972568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials.
    Roviello G; Gatta Michelet MR; D'Angelo A; Nobili S; Mini E
    Clin Transl Oncol; 2020 Jul; 22(7):1033-1039. PubMed ID: 31617061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    Wang L; Paller C; Hong H; Rosman L; De Felice A; Brawley O; Alexander GC
    J Natl Cancer Inst; 2022 Feb; 114(2):191-202. PubMed ID: 33830214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer.
    Smith MR; Mehra M; Nair S; Lawson J; Small EJ
    Clin Genitourin Cancer; 2020 Apr; 18(2):e180-e189. PubMed ID: 31980408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
    Hird AE; Magee DE; Bhindi B; Ye XY; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z; Wallis CJD
    Clin Genitourin Cancer; 2020 Oct; 18(5):343-350. PubMed ID: 32278840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
    Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
    JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
    Rodriguez-Vida A; Rodríguez-Alonso A; Useros-Rodríguez E; Lopez-Campos F; Amor-Carro O; Arribas-Ruiz A; Martinez-Torres J; Roca-Pardiñas J; Quesada-García A; Muñoz-Del-Toro JR; Juárez-Soto Á
    Clin Genitourin Cancer; 2022 Apr; 20(2):197.e1-197.e10. PubMed ID: 34920959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
    Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; De Cobelli O; Nolè F
    Eur J Cancer; 2015 Sep; 51(14):1970-7. PubMed ID: 26169016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.